🔎 Trials Near Me

Akèy › Leksemi mieloïd egi › Kentucky › Lexington

Etid klinik pou Leksemi mieloïd egi nan Lexington, KY

10 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Lexington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Ap rekriteFaz 2
  • University of Kentucky/Markey Cancer Center, Lexington
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • CommonSpirit Saint Joseph Hospital - Lexington, Lexington
  • Saint Joseph Radiation Oncology Resource Center, Lexington
  • CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • University of Kentucky/Markey Cancer Center, Lexington
Laj 18 a 59 · Tout sèks · Mizajou Sep 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Ap rekriteFaz 3
  • University of Kentucky Markey Cancer Center, Lexington
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06852222

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • University of Kentucky/Markey Cancer Center, Lexington
Laj 18 a 59 · Tout sèks · Mizajou Sep 22, 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • University of Kentucky/Markey Cancer Center, Lexington
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Ap rekriteFaz 3
  • University of Kentucky/Markey Cancer Center, Lexington
6 Months – 21 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Ap rekriteFaz 3
  • University of Kentucky/Markey Cancer Center, Lexington
Laj 1 a 25 · Tout sèks · Mizajou Sep 4, 2026 · NCT07022678

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ap rekriteFaz 3
  • University of Kentucky, Lexington
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312

Etid Leksemi mieloïd egi nan lòt vil

Lòt etid nan Lexington

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.